Nov. 11, 2024 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) -- -- Progressing through court-administered financial restructuring process with continued interest from multiple parties Nov. 11, 2024 -- Gritstone bio, Inc. (OTC: GRTSQ), a clinical-stage biotechnology company working to de

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing Dose-dependent exposure was observed with evidence of robust brain penetration Data supports potential advancement into Phase 2 for neurodegenerative diseases characterized by neuroinflammation such as Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease Nov. 11, 2024 -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies f

Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically “cold” tumors Complete resolution of a metastatic liver lesion observed in a patient with microsatellite stable colorectal cancer (MSS CRC) Safety data indicated combination of vilastobart and atezolizumab was generally well-tolerated and support the potential of vilastobart to be a di

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could potentially provide a meaningful advance in treatment in the global $1

AM003 is a first-in-class functional oligonucleotide in development for the treatment of solid tumors First –in-human, monotherapy dose-escalation Phase 1 trial has been successfully completed The study met its primary endpoint of safety and tolerability Nov. 07, 2024 -- Aummune, a clinical –stage biopharmaceutical company developing a unique class of oligonucleotide drugs to treat solid tumors, announced today the completion of a Phase 1 trial of its proprietary investigational product AM003,

Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab) ORR of 50% in 1L patients treated with CUE-101 and pembrolizumab with low PD-L1 expression (combined positive score (CPS) 1-19) 67% overall disease control rate (DCR) in late-stage pancreatic cancer patients treated with CUE-102 monotherapy, including an unconfirmed partial re

Nov. 08, 2024 -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company’s offices in London, shareholders approved the Company’s issuance of shares in connection

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in Phase 1 Solid Tumor Study Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State at Day 8 Following Treatment Nov. 09, 2024 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to b

Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract Nov. 09, 2024 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company’s adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in the treatment of metastatic castration resistant prostate cancer (mCRPC). The d